SAN DIEGO, Oct. 13, 2016 /PRNewswire/ -- Halozyme Therapeutics,
Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly
Update Conference Call for the third quarter 2016 on Mon., Nov. 7, 2016 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley,
president and chief executive officer, will lead the call. On the same date post-market, Halozyme will release financial results
for the third quarter 2016.
The call will be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made
available following the close of the call. To access the webcast and additional documents related to the call, please visit
www.halozyme.com approximately fifteen minutes prior to the
call to register, download and install any necessary audio software. The live call may be accessed by calling (877) 410-5657
(domestic callers) or (334) 323-7224 (international callers) using passcode 769890. A telephone replay will be available after
the call by dialing (877) 919-4059 (domestic callers) or (334) 323-0140 (international callers) using replay ID number
22039188.
About Halozyme
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target
the tumor microenvironment. Halozyme's lead proprietary program, investigational drug PEGPH20, applies a unique approach to
targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor in animal models. PEGPH20
is currently in development for metastatic pancreatic cancer, non-small cell lung cancer, gastric cancer, metastatic breast
cancer and has potential across additional cancers in combination with different types of cancer therapies. In addition to its
proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies
including Roche, Baxalta, Pfizer, Janssen, AbbVie and Lilly for its ENHANZE™ drug delivery platform. Halozyme is headquartered in
San Diego. For more information visit www.halozyme.com.
Contacts:
Jim Mazzola
858-704-8122
ir@halozyme.com
Chris Burton
858-704-8352
ir@halozyme.com
Logo - http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/halozyme-to-host-third-quarter-2016-financial-results-conference-call-300344668.html
SOURCE Halozyme Therapeutics, Inc.